Member News
Health Canada Approves KEYTRUDA® as Monotherapy for the Treatment of Adult and Pediatric Patients with Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumours that have Progressed Following Prior Treatment and who have No Satisfactory Alternative Treatment Options
KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a monotherapy… Read More
